Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Fumaric Acid Esters" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The fumaric acid esters (FAE) monoethylfumarate (MEF) and dimethylfumarate (DMF) are chemical compounds derived from the base compound fumaric acid. Fumaric acid is a food additive commonly found in sweets and cakes. In this chemical state, fumaric acid is poorly absorbed and passes straight through the body without causing any effects.
Method of preparing an aliphatic polyurea spray elastomer system
This invention concerns a method for the preparation of polyurea elastomers, comprising: (a) reacting an amine chain extender with dialkyl maleate to form an aspartic ester, wherein the chain extender has a molar amount of amine groups that is less than the moles of dialkyl maleate; (b) blending the aspartic ester with one or more polyoxyalkyleneamines to prepare a resin blend; (c) contacting the resin blend with an isocyanate under conditions effective to form a polyurea elastomer. This invention also concerns a a polyurea elastomer, comprising the reaction product of (a) a resin blend containing one or more polyoxyalkyleneamine and an aspartic ester and (b) an isocyanate, wherein the aspartic ester in the resin blend comprises a reaction product of an amine chain extender and a dialkyl maleate, wherein the mole ratio of amine functionality in the amine chain extender to dialkyl maleate or fumarate is greater than 1:1.
Owner:JPMORGAN CHASE BANK N A AS COLLATERAL AGENT +1
Controlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
Owner:BIOGEN SWISS MFG GMBH
Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders
The present invention relates to compositions, kits and methods for administration of a first component of fumaric acid ester(s), or a pharmaceutically acceptable salt thereof, and a second component which is a substance that reduces or eliminates flushing.
Owner:BIOGEN SWISS MFG GMBH
Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester
InactiveUS20080299196A1Decrease glass transition pointLow film forming temperatureBiocideSenses disorderDiseaseHigh concentration
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designed to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
Owner:BIOGEN SWISS MFG GMBH
Pharmaceutical composition comprising one or more fumaric acid esters
InactiveUS20120034274A1Reduce degradationImprove toleranceOrganic active ingredientsBiocideControlled releaseFumaric acid
Owner:BIOGEN SWISS MFG GMBH
Pharmaceutical composition comprising one or more fumaric acid esters
InactiveUS20130259906A1Reduce degradationImprove toleranceOrganic active ingredientsBiocideControl releaseFumaric acid
Owner:BIOGEN SWISS MFG GMBH
Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
ActiveUS20120034303A1Sufficient bioavailabilityLow variabilityBiocideSenses disorderDrugFumaric Acid Esters
Owner:BIOGEN SWISS MFG GMBH
Controlled release pharmaceutical compositions comprising a fumaric acid ester
InactiveUS20130315993A1Improve bioavailabilitySuitable for processingBiocidePowder deliveryControlled releaseMedicine
The invention features a kit. The kit includes: (i) a first unit dosage form consisting essentially of about 120 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release; and (ii) a second unit dosage form consisting essentially of about 240 mg of dimethylfumarate and one or more pharmaceutically acceptable excipients, wherein the dimethylfumarate is formulated for delayed release.
Owner:BIOGEN SWISS MFG GMBH
Method of making alternating copolymers of isobutylene type monomers
A method of making a copolymer composition containing a copolymer, which includes the steps of (a) providing a donor monomer composition that includes an isobutylene type monomer; (b) mixing the donor monomer composition with an ethylenically unsaturated monomer composition that includes one or more ethylenically unsaturated acceptor monomers, and is substantially free of maleate type monomers and fumarate type monomers, and (c) polymerizing the mixture resulting from step (b) in the presence of a free radical polymerization initiator. The polymerization is carried out in the substantial absence of Lewis acids and / or transition metals. The isobutylene type monomer is present at a molar excess of at least 10 mol % based on the molar concentration of monomers in the ethylenically unsaturated monomer composition. The ethylenically unsaturated acceptor monomers are present in an amount of at least 15 mol % of the total monomer composition.
Owner:PPG IND OHIO INC
Controlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
Owner:前进药物股份公司
Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
ActiveUS8906420B2Sufficient bioavailabilityLow variabilityOrganic active ingredientsSenses disorderControlled releasePharmaceutical formulation
A pharmaceutical formulation comprising an erosion matrix comprising one or more fumaric acid esters as well as one or more rate-controlling agents, wherein erosion of said erosion matrix permits controlled release of said fumaric acid ester(s).
Owner:BIOGEN SWISS MFG GMBH
Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
InactiveUS20140171504A1Improve update processHigh expressionBiocideAmide active ingredientsBeta thalassemiaSickle-cell disorders
Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
Owner:AUGUSTA UNIV RES INST INC
In-situ preparation of polyaspartic ester mixture
InactiveCN1362946AOrganic compound preparationAmino-carboxyl compound preparationOrganic chemistryFumaric Acid Esters
A method for making a polyaspartic ester mixture in-situ comprising the sequential steps of (a) reacting a cyclic amine with an excess amount of an ester of fumaric or maleic acid to form a mixture containing first polyaspartic ester component and excess unreacted ester of fumaric or maleic acid, and (b) adding an acyclic amine to the mixture resulting from step (a) and reacting the acyclic amine with the excess ester of fumaric or maleic acid to form a second polyaspartic ester component.
Owner:BAYER CORP
Gel coat compositions from acrylate-modified aspartates
A coating composition is provided. The composition comprises as component I, a) a polyaspartic acid ester comprising the reaction product of one more diamines, one or more difunctional acrylate-containing compounds and one or more maleic / fumaric acid esters; b) at least one moisture scavenger; c) at least one deaerator; d) at least one plasticizer; and e) optionally additives; and as component II, one or more polyisocyanates. Methods of making and applying the composition to a substrate are also provided. The coating is particularly suitable for use as a gel coat.
Owner:BAYER MATERIALSCIENCE AG
Acrylate-modified aspartates and gel coat compositions made therefrom
A coating composition is provided. The composition comprises as component I, a) a polyaspartic acid ester comprising the reaction product of one more diamines, one or more difunctional acrylate-containing compounds and one or more maleic / fumaric acid esters; b) at least one moisture scavenger; c) at least one deaerator; d) at least one plasticizer; and e) optionally additives; and as component II, one or more polyisocyanates. Methods of making and applying the composition to a substrate are also provided. The coating is particularly suitable for use as a gel coat.
Owner:COVESTRO LLC
Method for preventing fumaric acid deposits in the production of maleic acid anhydride
InactiveUS20090143601A1Improve industrial scale preparationHigh complexityOrganic compound preparationMetal/metal-oxides/metal-hydroxide catalystsFumaropimaric acidOrganic solvent
The present invention provides a process for preventing fumaric acid deposits in the preparation of maleic anhydride, comprising the following steps:a) absorption of a C4-dicarboxylic acid or of a derivative from a crude product mixture into an organic solvent or water as an absorbent,b) removal of the C4-dicarboxylic acid or of a derivative from the absorbent,the absorbent thus recovered being catalytically hydrogenated fully or partly and recycled fully or partly into the absorption stage (a).
Owner:BASF AG
Method for preparing fumaric acid ester by using plant straws
InactiveCN101863765AHigh yieldHigh purityOrganic compound preparationCarboxylic acid esters preparationFumaropimaric acidPolyester
The invention discloses a method for preparing fumaric acid ester by using plant straws. The method comprises the following sequential steps: 1) leading the plant straws to carry out acid hydrolysis reaction so as to prepare furfural; 2) leading the furfural to carry out oxidation reaction so as to prepare fumaric acid; and 3) leading the fumaric acid and 2-octanol to carry out esterification reaction so as to prepare the fumaric acid ester. The 2-octanol fumaric acid ester prepared by the method not only is the main indispensable raw material for producing novel high-performance synthetic lubricating oil polyester oil, but also has high product purity and high yield; and in addition, the invention also opens up a new material resource and method for producing the 2-octanol fumaric acid ester, and provides a practical way for industrial production of the 2-octanol fumaric acid ester and the plant straws and comprehensive utilization of the plant straws.
Owner:北京雷恩新材料科技有限公司
Acrylate-modified aspartates and gel coat compositions made therefrom
Owner:COVESTRO LLC
Poly-butyl glycol fumaric acid ester-based material for environment-friendly LED packaging adhesive and preparation method of poly-butyl glycol fumaric acid ester-based material
ActiveCN105860908AHigh light transmittanceHigh refractive indexNon-macromolecular adhesive additivesCross-linkPolymer science
The invention provides a poly-butyl glycol fumaric acid ester-based material for an environment-friendly LED packaging adhesive and a preparation method of the poly-butyl glycol fumaric acid ester-based material. A final curing product is a PBF / PPF-DA cross-linking solidified body, namely, a poly-butyl glycol fumaric acid ester / poly-butyl glycol fumaric acid ester diacrylic ester cross-linking solidified body, the solidified product is free of toxicity, the solidification time can be controlled within a relatively short time range by adjusting the lighting intensity and the distance between a light source and a sample, the requirements of LED packaging on the solidification time can be greatly met, and the solidified product is relatively good in light transmittance, refractive index, thermal stability and mechanical property.
Owner:XI AN JIAOTONG UNIV
Resin composition, optical compensation film employing same, and production method for same
Provided are a resin composition characterized by containing 30-99 mass% of a cellulose resin represented by general formula (1) below, and 70-1 mass% of a fumaric acid ester polymer containing 30 mol% or more of fumaric acid residue units represented by general formula (2) below; an optical compensation film employing the same; and a production method for an optical compensation film. (1) (2) (In the formulas, R1-R3 represent C1-12 substituent groups, and R4 and R5 represent C1-12 alkyl groups.)
Owner:TOSOH CORP
Automobile lubricating oil
ActiveCN104388149AExcellent high temperature detergencyExcellent antioxidant stabilityAdditivesPhosphatePhosphoric acid
The invention discloses automobile lubricating oil. The automobile lubricating oil comprises the following raw materials by weight percentage: 2-3% of barium salt of phosphosulfurized polyisobutylene, 0.5-2% of N-phenyl-a-naphthylamine, 0.5-1.5% of tricresyl phosphate, 1.0-20% of polyisobutene, 0.5-3% of zinc naphthenate, 0.1-1.0% of styrene fumaric acid ester copolymer, 1-3% of methylsilicone oil, 1-3% of anitimony diisopropyl dithio phosphate, 1-3% of glyceryl monooleate and the balance of base oil. Compared with the prior art, the automobile lubricating oil has the benefits that the high-temperature cleanliness, the oxidation stability, the antifriction and abrasive resistance, and the base value retainability are excellent, the average oil consumption is low, the engine noise and the engine vibration are reduced, the automobile runs more stably, and the driving control performance is remarkably improved.
Owner:深圳易省油节能科技有限公司
Supporting immunomodulatory agent
The invention relates to a combination therapy for the prevention and / or treatment of immune-mediated chronic inflammatory and autoimmune diseases comprising a combination of one or more C3-C8 carboxylic acids, physiologically acceptable salts and / or esters thereof, and one or more fumaric acid esters and / or salts thereof. The combination being particularly useful in the treatment of psoriasis and multiple sclerosis.
Owner:FLEXOPHARM BRAIN GMBH & CO KG
Composition
InactiveUS20140308427A1Reduce the amount requiredExtension of timeOrganic compound preparationFatty substance preservation using additivesFatty acidFatty alcohol
There is provided a palm olein composition comprising: (a) palm olein oil (b) (i) a lactic acid ester selected from an ester of lactic acid and a C12 to C22 fatty acid, salts thereof and mixtures thereof; or (ii) a fumaric acid ester selected from an ester of fumaric acid and a C12 to C22 fatty alcohol, salts thereof and mixtures thereof.
Owner:DUPONT NUTRITION BIOSCIENCES APS
Methods of Treating Sickle Cell Disease and Related Disorders Using Fumaric Acid Esters
Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
Owner:AUGUSTA UNIV RES INST INC
Radiation-curing binders containing carboxylic acid esters
The present invention relates to novel radiation-curing powder coating binders containing maleic and / or fumaric acid esters and one or more amorphous or partially crystalline resins containing at least one group that reacts with ethylenically unsaturated compounds under the action of actinic radiation to form a polymer. The binders have a glass transition temperature ranging from 30 to 90° C. The binders can be used as a constituent in coating compositions.
Owner:ALLNEX NETHERLANDS BV
Preparation method for fumarate copolymer pour point depressant for lubricating oil
InactiveCN107857840AImprove pour point depressing effectImprove performanceLubricant compositionCarbon numberBenzoyl peroxide
The invention relates to a preparation method for a fumarate copolymer pour point depressant for lubricating oil. The method mainly comprises the following steps: selecting fumaric acid, a higher alcohol (carbon number 8-18), vinyl acetate, styrene, toluene, and benzoyl peroxide (BPO), wherein the fumaric acid and the higher alcohol (carbon number 8-18) are analytical reagents and purchased froma Tianjin Guangfu fine chemical research institute; the vinyl acetate, the styrene and the toluene are analytical reagents and purchased from a Beijing chemical work; and the benzoyl peroxide (BPO) isan analytical reagent. According to the invention, the fumarate copolymer pour point depressant for the lubricating oil prepared by the method has excellent pour point depressing performance in a plurality of base oil, and is a novel pour point depressant with excellent performance for the lubricating oil, and has higher application value and broad market prospects.
Owner:SHAANXI YIPINDA PETROCHEM CO LTD
Polyurea compositions from polyaspartic esters and secondary heterocyclic amines derived aspartic esters
PendingUS20210147708A1Safer and more environmentally friendlyPolyurea/polyurethane coatingsPolymer scienceHeterocyclic amine
The present invention relates to a polyurea coating composition comprising (A) a polyisocyanate; (B) a polyaspartic ester; and (C) an aspartic ester. The polyaspartic ester (B) is represented by the structure below:where Z=a cycloalkyl, alkyl or aryl group, R1, R2=alkyl groups containing 1-10 carbon atoms; and n=2-4. The aspartic ester (C) is derived from a secondary heterocyclic amine in a 3-7 membered ring compound bearing at least one secondary amine functionality. This invention also relates to use of a polyurea coating composition comprising (A)-(C) for the preparation of a polyurea coating. This invention further relates to a process for preparing a polyaspartic / aspartic ester mixture in-situ by initially reacting an ester of fumaric acid or maleic acid with a polyamine and then reacting the unreacted ester of fumaric acid or maleic acid to completion with a secondary heterocyclic amine. This method makes it possible to prepare a polyurea coating without maleic acid or fumaric acid esters thereby providing a safer and more environmentally friendly product.
Owner:EVONIK OPERATIONS GMBH
Fumaric acid diester-cinnamic acid ester copolymer, method for producing same, and film using same
The present invention provides a new high-molecular-weight fumaric acid diester-cinnamate copolymer that can be expected to maintain excellent strength or have excellent toughness when it is formed into a film, a method for efficiently producing it, and a method using its membrane. Fumaric acid diester-cinnamic acid ester copolymer containing fumaric acid diester residue units, cinnamate residue units having an alkyl group having 1 to 6 carbon atoms, and having two or more radically polymerizable functional groups residue units of multifunctional monomers.
Owner:TOSOH CORP
Radiation-curing binders containing carboxylic acid esters
The present invention relates to novel radiation-curing powder coating binders containing maleic and / or fumaric acid esters and one or more amorphous or partially crystalline resins containing at least one group that reacts with ethylenically unsaturated compounds under the action of actinic radiation to form a polymer. The binders have a glass transition temperature ranging from 30 to 90° C. The binders can be used as a constituent in coating compositions.
Owner:ALLNEX NETHERLANDS BV
Synthetic method of β-ester group-γ-butyrolactam and γ-ester group-δ-valerolactam
ActiveCN106748952BSimple and fast operationMild reaction conditionsOrganic chemistryGlutaratesAlkylation
The invention belongs to the technical field of chemical engineering, and in particular relates to a method for synthesizing beta-ester group-gamma-butyrolactam and gamma-ester group-delta-valerolactam. The method comprises the following steps: by taking ZnEt2 as an alkylation reagent, performing selective alkylation on fumaric acid ester, itaconic acid ester and methylic glutarate at near room-temperature, and performing Mannich addition on imine, and performing a cyclization reaction. The method provided by the invention is common in reaction raw material and low in price, a transition metal catalyst is not needed, one-pot method synthesis is achieved in a same reaction container through serial reactions, separation process and product loss can be reduced, the method is simple and convenient to operate, efficient in process and mild in condition, and the reactions can be implemented at normal temperature or near room-temperature.
Owner:DALIAN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com